Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 extension study in psoriatic arthritis
NCT01169844Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Jun 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01169844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01169844.